Intellia Therapeutics, Inc. (NTLA)
Last updated: 2026-11-19 02:40:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Intellia Therapeutics, Inc. (NTLA) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $9.77, with a market capitalization of $1.38B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.95 to $18.48. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.38B | |
$9.87 | |
$10.47 | |
$9.66 | |
$9.78 | |
5.28M | |
4.73M | |
-- | |
$18.48 | |
$7.95 | |
-- | |
2026-09-30 |
Intellia Therapeutics, Inc. (NTLA) Latest Closing Stock Price
Intellia Therapeutics, Inc. (NTLA) last closed at $9.77 as of 2026-11-19 01:00:00, down 0.05% ($0.00) from the previous close of $9.78.
During the latest regular trading session, NTLA traded between $9.67 and $10.47, with a volume of 5.28M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Intellia Therapeutics, Inc. (NTLA) 7-Day Stock Price Change
Over the past seven days, Intellia Therapeutics, Inc. (NTLA) moved from $12.11 to $9.77, representing a decline of 19.34% ($2.34).
The stock traded between $9.67 and $12.15 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 5.87 million shares, up versus the previous seven-day period, indicating higher trading activity.
NTLA 52-Week Price Position
Position in Range: 17.3%
NTLA is currently trading at $9.77, placing it 17.3% of the way from its 52-week low of $7.95 to its 52-week high of $18.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Intellia Therapeutics, Inc. (NTLA)?
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Intellia Therapeutics, Inc. Information
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 377 |
| Exchange | NASDAQ |
| Company Website |
NTLA News
Latest news related to Intellia Therapeutics, Inc. and NTLA stock.
- Read Full Article
- Read Full Article
Intellia Says HAELO Met Key Secondary Quality-Of-Life Endpoint; No Serious Adverse Events In Lonvo-Z Arm
- Read Full Article
Intellia Says 89% Overall Attack Rate Reduction Across 93 Patients Over Up To 4 Years After One-Time Lonvo-Z Dose; All LTP-Free At Latest Follow-Up
- Read Full Article
Intellia Says Lonvo-Z Cut HAE Attack Rate 81% Vs Prior Long-Term Prophylaxis In Phase 3 HAELO Patients
- Read Full Article
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
Intellia Therapeutics announced positive clinical data for lonvo-z, its one-time CRISPR gene editing treatment for hereditary angioedema (HAE), presented at ACAAI 2026. Key findings include an 81% reduction in monthly attack rates for patients previously on long-term prophylaxis, with 100% of patients becoming prophylaxis-free. Patient interviews showed 96% described lonvo-z as optimal therapy. The FDA accepted the BLA with Priority Review and a PDUFA target action date of March 10, 2027.
Ways to Trade NTLA at MEXC
How to Buy Intellia Therapeutics, Inc. (NTLA) Stock on MEXC
Eligible investors can buy real shares of Intellia Therapeutics, Inc. (NTLA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Intellia Therapeutics, Inc. (NTLA) stock price today?
2.Is NTLA stock going up or down today?
3.What is NTLA pre-market price?
4.What is NTLA after-hours price?
5.Is NTLA stock trading now?
6.Where does NTLA sit relative to its 52-week high and low?
7.What sector is Intellia Therapeutics, Inc. in?
8.What is Intellia Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is NTLA valued in terms of P/E ratio and EPS?
10.Does Intellia Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Compliance Disclosure and Data Source
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to NTLA, including Stocks, Tokenized Stocks, and Stock Futures.
Disclaimer
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Search Stocks
NTLA Stock Calculator
Estimate the value between NTLA shares and USD.
NTLA Shares to USD
1.00 NTLA shares = 9.768 USD
Calculations are estimates based on the latest available price and are for reference only.


